Kidney Cancer

Latest News

FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC
FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC

October 29th 2024

The RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.

Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC
Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC

September 25th 2024

Benmelstobart plus anlotinib improves PFS, ORR vs sunitinib in aRCC
Benmelstobart plus anlotinib improves PFS, ORR vs sunitinib in aRCC

September 19th 2024

Serum glycoproteins may predict response to nivolumab/cabozantinib in aRCC
Serum glycoproteins may predict response to nivolumab/cabozantinib in aRCC

September 16th 2024

Ipilimumab / nivolumab significantly improves 12-month nccRCC survival in SUNNIFORECAST
Ipilimumab / nivolumab significantly improves 12-month nccRCC survival in SUNNIFORECAST

September 14th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.